Recursion Pharmaceuticals, Inc.’s (NASDAQ:RXRX) Share Price Could Signal Some Risk
You may think that with a price-to-sales (or “P/S”) ratio of 29.9x Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a stock to avoid completely, seeing as almost half of all the Biotechs companies in the United States have P/S ratios under 12.7x and even P/S lower than 4x aren’t out of the ordinary. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly elevated P/S.
See our latest analysis for Recursion Pharmaceuticals
What Does Recursion Pharmaceuticals’ Recent Performance Look Like?
With revenue growth that’s inferior to most other companies of late, Recursion Pharmaceuticals has been relatively sluggish. It…
